100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R44NS084575
Award Date
7/1/14
Completion Date
8/31/26
Dollars Obligated
$4.7M
Overview
Activity
10
Transactions
10
Subawards
Similar Awards
Federal Agency
National Institute of Neurological Disorders and Stroke
Awardee
Prothera Biologics, Inc. (ZAE3CABBMZE9)
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Rhode Island, USA
Update #1
Update #2
INTER-ALPHA INHIBITORS IN HYPOXIC-ISCHEMIC BRAIN INJURY
Posted 6/9/17
5
1
2
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
INTER-ALPHA INHIBITORS IN HYPOXIC-ISCHEMIC BRAIN INJURY - NEONATAL HYPOXIA-ISCHEMIA (HI) REMAINS A MAJOR CAUSE OF ACUTE PERINATAL BRAIN INJURY, LEADING ULTIMATELY TO NEUROLOGIC DYSFUNCTION MANIFESTING AS CEREBRAL PALSY, MENTAL RETARDATION, AND EPILEPSY. UNFORTUNATELY, CURRENT TREATMENT AND PREVENTION STRATEGIES IN NEWBORNS ARE LIMITED. THERE ARE NO CURRENTLY AVAILABLE THERAPIES TO PREVENT/TREAT AND/OR ATTENUATE BRAIN DAMAGE IN PREMATURE INFANTS OTHER THAN SUPPORTIVE CARE AND THE ONLY AVAILABLE THERAPEUTIC INTERVENTION FOR FULL TERM INFANTS IS HYPOTHERMIA, WHICH IS ONLY PARTIALLY PROTECTIVE. INTER- ALPHA INHIBITOR PROTEINS (IAIP) ARE NATURALLY DERIVED GLYCOPROTEINS THAT HAVE BEEN SHOWN TO PLAY AN IMPORTANT ROLE IN MODULATING INFLAMMATORY RESPONSES BY DOWN-REGULATING PRO-INFLAMMATORY CYTOKINES IN SEVERAL EXPERIMENTAL MODELS OF NEWBORN AND ADULT SYSTEMIC INFLAMMATION AND IN MODELS OF INFLAMMATION-INDUCED PREMATURE LABOR. OUR RECENT INVESTIGATIONS STRONGLY DEMONSTRATE THAT IAIP REDUCED NEUROANATOMICAL INJURY IN THE BRAIN OF NEONATAL RATS AND IMPROVES LONG-TERM BEHAVIORAL INDICES OF LEARNING AND MEMORY TASKS. IN THE PHASE I SBIR STUDY, WE CONFIRMED THE BENEFICIAL EFFECTS OF IAIP IN NEONATAL RATS AFTER HI, PARTICULARLY IN MALE SUBJECTS. MORE RECENTLY, WE OBTAINED SUPPORTING EVIDENCE THAT IAIP ALSO HAS LONG-TERM BENEFICIAL EFFECTS ON BEHAVIORAL FUNCTION IN FEMALE RATS, SUGGESTING THAT IAIP HAS DURABLE NEUROPROTECTIVE EFFECTS IN BOTH MALES AND FEMALES DEPENDING UPON TEST AND THE DURATION AFTER THE HI INSULT. THESE FINDINGS SUGGEST UNIQUE BENEFICIAL EFFECTS OF IAIP ON LONG-TERM OUTCOMES IN MALES AND FEMALES, IN SPITE OUR HISTOPATHOLOGICAL BENEFICIAL FINDINGS MAINLY IN MALE NEONATAL RATS. THE GOAL OF THIS PHASE II SBIR PROJECT IS TO OBTAIN ROBUST PRECLINICAL AND MANUFACTURING PROCESS DATA OF HUMAN PLASMA-DERIVED IAIP TO SUPPORT THE DEVELOPMENT AS A NOVEL ADJUNCTIVE NEUROPROTECTIVE STRATEGY TO THE CURRENT STANDARD OF CARE OF HYPOTHERMIA FOR THE TREATMENT OF HYPOXIC-ISCHEMIC ENCEPHALOPATHY IN NEWBORNS. WE HYPOTHESIZE THAT TREATMENT WITH IAIP AS AN ADJUNCTIVE THERAPY TO HYPOTHERMIA FURTHER ENHANCES THE EFFECTIVENESS OF HYPOTHERMIA AS A NEUROPROTECTIVE STRATEGY AND IMPROVES LONG-TERM OUTCOMES AFTER HI BRAIN INJURY IN NEONATES. THE SPECIFIC AIMS OF THE STUDIES ARE: 1) TO DEVELOP AN EFFICIENT SCALABLE BIOPROCESS OF PLASMA-DERIVED IAIP AND CARRY OUT FORMULATION, VIRAL SAFETY AND LONG-TERM STABILITY STUDIES OF PURIFIED IAIP; 2A) TO DETERMINE THE PHARMACOKINETICS (PK) OF IAIP IN MALE AND FEMALE RATS UNDER CONDITIONS OF HYPOXIC-ISCHEMIC (HI) AND HYPOTHERMIA (HT) AND TO PERFORM DOSE-RESPONSE STUDIES; 2B) TO ASSESS THE NEUROPROTECTIVE EFFECTS OF IAIP AS AN ADJUNCTIVE TREATMENT STRATEGY TO HT IN MODERATE OR SEVERE HI BRAIN INJURY IN NEWBORN RATS AND 3) TO DETERMINE THE LONG-TERM NEUROPROTECTIVE EFFICACY OF IAIP TREATMENT WITH COMBINED HT AFTER HI IN THE NEWBORN RATS. THE PROPOSED STUDIES HAVE SIGNIFICANT TRANSLATIONAL POTENTIAL TO DEVELOP IAIP AS A NOVEL AGENT TO PREVENT/ATTENUATE BRAIN DAMAGE IN FULL TERM AS WELL AS IN PRETERM INFANTS AT RISK FOR MENTAL RETARDATION.
$2.8m
9/7/23
Not listed
INTER-ALPHA INHIBITORS IN HYPOXIC-ISCHEMIC BRAIN INJURY - NEONATAL HYPOXIA-ISCHEMIA (HI) REMAINS A MAJOR CAUSE OF ACUTE PERINATAL BRAIN INJURY, LEADING ULTIMATELY TO NEUROLOGIC DYSFUNCTION MANIFESTING AS CEREBRAL PALSY, MENTAL RETARDATION, AND EPILEPSY. UNFORTUNATELY, CURRENT TREATMENT AND PREVENTION STRATEGIES IN NEWBORNS ARE LIMITED. THERE ARE NO CURRENTLY AVAILABLE THERAPIES TO PREVENT/TREAT AND/OR ATTENUATE BRAIN DAMAGE IN PREMATURE INFANTS OTHER THAN SUPPORTIVE CARE AND THE ONLY AVAILABLE THERAPEUTIC INTERVENTION FOR FULL TERM INFANTS IS HYPOTHERMIA, WHICH IS ONLY PARTIALLY PROTECTIVE. INTER- ALPHA INHIBITOR PROTEINS (IAIP) ARE NATURALLY DERIVED GLYCOPROTEINS THAT HAVE BEEN SHOWN TO PLAY AN IMPORTANT ROLE IN MODULATING INFLAMMATORY RESPONSES BY DOWN-REGULATING PRO-INFLAMMATORY CYTOKINES IN SEVERAL EXPERIMENTAL MODELS OF NEWBORN AND ADULT SYSTEMIC INFLAMMATION AND IN MODELS OF INFLAMMATION-INDUCED PREMATURE LABOR. OUR RECENT INVESTIGATIONS STRONGLY DEMONSTRATE THAT IAIP REDUCED NEUROANATOMICAL INJURY IN THE BRAIN OF NEONATAL RATS AND IMPROVES LONG-TERM BEHAVIORAL INDICES OF LEARNING AND MEMORY TASKS. IN THE PHASE I SBIR STUDY, WE CONFIRMED THE BENEFICIAL EFFECTS OF IAIP IN NEONATAL RATS AFTER HI, PARTICULARLY IN MALE SUBJECTS. MORE RECENTLY, WE OBTAINED SUPPORTING EVIDENCE THAT IAIP ALSO HAS LONG-TERM BENEFICIAL EFFECTS ON BEHAVIORAL FUNCTION IN FEMALE RATS, SUGGESTING THAT IAIP HAS DURABLE NEUROPROTECTIVE EFFECTS IN BOTH MALES AND FEMALES DEPENDING UPON TEST AND THE DURATION AFTER THE HI INSULT. THESE FINDINGS SUGGEST UNIQUE BENEFICIAL EFFECTS OF IAIP ON LONG-TERM OUTCOMES IN MALES AND FEMALES, IN SPITE OUR HISTOPATHOLOGICAL BENEFICIAL FINDINGS MAINLY IN MALE NEONATAL RATS. THE GOAL OF THIS PHASE II SBIR PROJECT IS TO OBTAIN ROBUST PRECLINICAL AND MANUFACTURING PROCESS DATA OF HUMAN PLASMA-DERIVED IAIP TO SUPPORT THE DEVELOPMENT AS A NOVEL ADJUNCTIVE NEUROPROTECTIVE STRATEGY TO THE CURRENT STANDARD OF CARE OF HYPOTHERMIA FOR THE TREATMENT OF HYPOXIC-ISCHEMIC ENCEPHALOPATHY IN NEWBORNS. WE HYPOTHESIZE THAT TREATMENT WITH IAIP AS AN ADJUNCTIVE THERAPY TO HYPOTHERMIA FURTHER ENHANCES THE EFFECTIVENESS OF HYPOTHERMIA AS A NEUROPROTECTIVE STRATEGY AND IMPROVES LONG-TERM OUTCOMES AFTER HI BRAIN INJURY IN NEONATES. THE SPECIFIC AIMS OF THE STUDIES ARE: 1) TO DEVELOP AN EFFICIENT SCALABLE BIOPROCESS OF PLASMA-DERIVED IAIP AND CARRY OUT FORMULATION, VIRAL SAFETY AND LONG-TERM STABILITY STUDIES OF PURIFIED IAIP; 2A) TO DETERMINE THE PHARMACOKINETICS (PK) OF IAIP IN MALE AND FEMALE RATS UNDER CONDITIONS OF HYPOXIC-ISCHEMIC (HI) AND HYPOTHERMIA (HT) AND TO PERFORM DOSE-RESPONSE STUDIES; 2B) TO ASSESS THE NEUROPROTECTIVE EFFECTS OF IAIP AS AN ADJUNCTIVE TREATMENT STRATEGY TO HT IN MODERATE OR SEVERE HI BRAIN INJURY IN NEWBORN RATS AND 3) TO DETERMINE THE LONG-TERM NEUROPROTECTIVE EFFICACY OF IAIP TREATMENT WITH COMBINED HT AFTER HI IN THE NEWBORN RATS. THE PROPOSED STUDIES HAVE SIGNIFICANT TRANSLATIONAL POTENTIAL TO DEVELOP IAIP AS A NOVEL AGENT TO PREVENT/ATTENUATE BRAIN DAMAGE IN FULL TERM AS WELL AS IN PRETERM INFANTS AT RISK FOR MENTAL RETARDATION.
$0
2/24/22
Not listed
INTER-ALPHA INHIBITORS IN HYPOXIC-ISCHEMIC BRAIN INJURY - NEONATAL HYPOXIA-ISCHEMIA (HI) REMAINS A MAJOR CAUSE OF ACUTE PERINATAL BRAIN INJURY, LEADING ULTIMATELY TO NEUROLOGIC DYSFUNCTION MANIFESTING AS CEREBRAL PALSY, MENTAL RETARDATION, AND EPILEPSY. UNFORTUNATELY, CURRENT TREATMENT AND PREVENTION STRATEGIES IN NEWBORNS ARE LIMITED. THERE ARE NO CURRENTLY AVAILABLE THERAPIES TO PREVENT/TREAT AND/OR ATTENUATE BRAIN DAMAGE IN PREMATURE INFANTS OTHER THAN SUPPORTIVE CARE AND THE ONLY AVAILABLE THERAPEUTIC INTERVENTION FOR FULL TERM INFANTS IS HYPOTHERMIA, WHICH IS ONLY PARTIALLY PROTECTIVE. INTER- ALPHA INHIBITOR PROTEINS (IAIP) ARE NATURALLY DERIVED GLYCOPROTEINS THAT HAVE BEEN SHOWN TO PLAY AN IMPORTANT ROLE IN MODULATING INFLAMMATORY RESPONSES BY DOWN-REGULATING PRO-INFLAMMATORY CYTOKINES IN SEVERAL EXPERIMENTAL MODELS OF NEWBORN AND ADULT SYSTEMIC INFLAMMATION AND IN MODELS OF INFLAMMATION-INDUCED PREMATURE LABOR. OUR RECENT INVESTIGATIONS STRONGLY DEMONSTRATE THAT IAIP REDUCED NEUROANATOMICAL INJURY IN THE BRAIN OF NEONATAL RATS AND IMPROVES LONG-TERM BEHAVIORAL INDICES OF LEARNING AND MEMORY TASKS. IN THE PHASE I SBIR STUDY, WE CONFIRMED THE BENEFICIAL EFFECTS OF IAIP IN NEONATAL RATS AFTER HI, PARTICULARLY IN MALE SUBJECTS. MORE RECENTLY, WE OBTAINED SUPPORTING EVIDENCE THAT IAIP ALSO HAS LONG-TERM BENEFICIAL EFFECTS ON BEHAVIORAL FUNCTION IN FEMALE RATS, SUGGESTING THAT IAIP HAS DURABLE NEUROPROTECTIVE EFFECTS IN BOTH MALES AND FEMALES DEPENDING UPON TEST AND THE DURATION AFTER THE HI INSULT. THESE FINDINGS SUGGEST UNIQUE BENEFICIAL EFFECTS OF IAIP ON LONG-TERM OUTCOMES IN MALES AND FEMALES, IN SPITE OUR HISTOPATHOLOGICAL BENEFICIAL FINDINGS MAINLY IN MALE NEONATAL RATS. THE GOAL OF THIS PHASE II SBIR PROJECT IS TO OBTAIN ROBUST PRECLINICAL AND MANUFACTURING PROCESS DATA OF HUMAN PLASMA-DERIVED IAIP TO SUPPORT THE DEVELOPMENT AS A NOVEL ADJUNCTIVE NEUROPROTECTIVE STRATEGY TO THE CURRENT STANDARD OF CARE OF HYPOTHERMIA FOR THE TREATMENT OF HYPOXIC-ISCHEMIC ENCEPHALOPATHY IN NEWBORNS. WE HYPOTHESIZE THAT TREATMENT WITH IAIP AS AN ADJUNCTIVE THERAPY TO HYPOTHERMIA FURTHER ENHANCES THE EFFECTIVENESS OF HYPOTHERMIA AS A NEUROPROTECTIVE STRATEGY AND IMPROVES LONG-TERM OUTCOMES AFTER HI BRAIN INJURY IN NEONATES. THE SPECIFIC AIMS OF THE STUDIES ARE: 1) TO DEVELOP AN EFFICIENT SCALABLE BIOPROCESS OF PLASMA-DERIVED IAIP AND CARRY OUT FORMULATION, VIRAL SAFETY AND LONG-TERM STABILITY STUDIES OF PURIFIED IAIP; 2A) TO DETERMINE THE PHARMACOKINETICS (PK) OF IAIP IN MALE AND FEMALE RATS UNDER CONDITIONS OF HYPOXIC-ISCHEMIC (HI) AND HYPOTHERMIA (HT) AND TO PERFORM DOSE-RESPONSE STUDIES; 2B) TO ASSESS THE NEUROPROTECTIVE EFFECTS OF IAIP AS AN ADJUNCTIVE TREATMENT STRATEGY TO HT IN MODERATE OR SEVERE HI BRAIN INJURY IN NEWBORN RATS AND 3) TO DETERMINE THE LONG-TERM NEUROPROTECTIVE EFFICACY OF IAIP TREATMENT WITH COMBINED HT AFTER HI IN THE NEWBORN RATS. THE PROPOSED STUDIES HAVE SIGNIFICANT TRANSLATIONAL POTENTIAL TO DEVELOP IAIP AS A NOVEL AGENT TO PREVENT/ATTENUATE BRAIN DAMAGE IN FULL TERM AS WELL AS IN PRETERM INFANTS AT RISK FOR MENTAL RETARDATION.
$0
2/24/22
Not listed
INTER-ALPHA INHIBITORS IN HYPOXIC-ISCHEMIC BRAIN INJURY - NEONATAL HYPOXIA-ISCHEMIA (HI) REMAINS A MAJOR CAUSE OF ACUTE PERINATAL BRAIN INJURY, LEADING ULTIMATELY TO NEUROLOGIC DYSFUNCTION MANIFESTING AS CEREBRAL PALSY, MENTAL RETARDATION, AND EPILEPSY. UNFORTUNATELY, CURRENT TREATMENT AND PREVENTION STRATEGIES IN NEWBORNS ARE LIMITED. THERE ARE NO CURRENTLY AVAILABLE THERAPIES TO PREVENT/TREAT AND/OR ATTENUATE BRAIN DAMAGE IN PREMATURE INFANTS OTHER THAN SUPPORTIVE CARE AND THE ONLY AVAILABLE THERAPEUTIC INTERVENTION FOR FULL TERM INFANTS IS HYPOTHERMIA, WHICH IS ONLY PARTIALLY PROTECTIVE. INTER- ALPHA INHIBITOR PROTEINS (IAIP) ARE NATURALLY DERIVED GLYCOPROTEINS THAT HAVE BEEN SHOWN TO PLAY AN IMPORTANT ROLE IN MODULATING INFLAMMATORY RESPONSES BY DOWN-REGULATING PRO-INFLAMMATORY CYTOKINES IN SEVERAL EXPERIMENTAL MODELS OF NEWBORN AND ADULT SYSTEMIC INFLAMMATION AND IN MODELS OF INFLAMMATION-INDUCED PREMATURE LABOR. OUR RECENT INVESTIGATIONS STRONGLY DEMONSTRATE THAT IAIP REDUCED NEUROANATOMICAL INJURY IN THE BRAIN OF NEONATAL RATS AND IMPROVES LONG-TERM BEHAVIORAL INDICES OF LEARNING AND MEMORY TASKS. IN THE PHASE I SBIR STUDY, WE CONFIRMED THE BENEFICIAL EFFECTS OF IAIP IN NEONATAL RATS AFTER HI, PARTICULARLY IN MALE SUBJECTS. MORE RECENTLY, WE OBTAINED SUPPORTING EVIDENCE THAT IAIP ALSO HAS LONG-TERM BENEFICIAL EFFECTS ON BEHAVIORAL FUNCTION IN FEMALE RATS, SUGGESTING THAT IAIP HAS DURABLE NEUROPROTECTIVE EFFECTS IN BOTH MALES AND FEMALES DEPENDING UPON TEST AND THE DURATION AFTER THE HI INSULT. THESE FINDINGS SUGGEST UNIQUE BENEFICIAL EFFECTS OF IAIP ON LONG-TERM OUTCOMES IN MALES AND FEMALES, IN SPITE OUR HISTOPATHOLOGICAL BENEFICIAL FINDINGS MAINLY IN MALE NEONATAL RATS. THE GOAL OF THIS PHASE II SBIR PROJECT IS TO OBTAIN ROBUST PRECLINICAL AND MANUFACTURING PROCESS DATA OF HUMAN PLASMA-DERIVED IAIP TO SUPPORT THE DEVELOPMENT AS A NOVEL ADJUNCTIVE NEUROPROTECTIVE STRATEGY TO THE CURRENT STANDARD OF CARE OF HYPOTHERMIA FOR THE TREATMENT OF HYPOXIC-ISCHEMIC ENCEPHALOPATHY IN NEWBORNS. WE HYPOTHESIZE THAT TREATMENT WITH IAIP AS AN ADJUNCTIVE THERAPY TO HYPOTHERMIA FURTHER ENHANCES THE EFFECTIVENESS OF HYPOTHERMIA AS A NEUROPROTECTIVE STRATEGY AND IMPROVES LONG-TERM OUTCOMES AFTER HI BRAIN INJURY IN NEONATES. THE SPECIFIC AIMS OF THE STUDIES ARE: 1) TO DEVELOP AN EFFICIENT SCALABLE BIOPROCESS OF PLASMA-DERIVED IAIP AND CARRY OUT FORMULATION, VIRAL SAFETY AND LONG-TERM STABILITY STUDIES OF PURIFIED IAIP; 2A) TO DETERMINE THE PHARMACOKINETICS (PK) OF IAIP IN MALE AND FEMALE RATS UNDER CONDITIONS OF HYPOXIC-ISCHEMIC (HI) AND HYPOTHERMIA (HT) AND TO PERFORM DOSE-RESPONSE STUDIES; 2B) TO ASSESS THE NEUROPROTECTIVE EFFECTS OF IAIP AS AN ADJUNCTIVE TREATMENT STRATEGY TO HT IN MODERATE OR SEVERE HI BRAIN INJURY IN NEWBORN RATS AND 3) TO DETERMINE THE LONG-TERM NEUROPROTECTIVE EFFICACY OF IAIP TREATMENT WITH COMBINED HT AFTER HI IN THE NEWBORN RATS. THE PROPOSED STUDIES HAVE SIGNIFICANT TRANSLATIONAL POTENTIAL TO DEVELOP IAIP AS A NOVEL AGENT TO PREVENT/ATTENUATE BRAIN DAMAGE IN FULL TERM AS WELL AS IN PRETERM INFANTS AT RISK FOR MENTAL RETARDATION.
$0
2/24/22
Not listed
INTER-ALPHA INHIBITORS IN HYPOXIC-ISCHEMIC BRAIN INJURY - NEONATAL HYPOXIA-ISCHEMIA (HI) REMAINS A MAJOR CAUSE OF ACUTE PERINATAL BRAIN INJURY, LEADING ULTIMATELY TO NEUROLOGIC DYSFUNCTION MANIFESTING AS CEREBRAL PALSY, MENTAL RETARDATION, AND EPILEPSY. UNFORTUNATELY, CURRENT TREATMENT AND PREVENTION STRATEGIES IN NEWBORNS ARE LIMITED. THERE ARE NO CURRENTLY AVAILABLE THERAPIES TO PREVENT/TREAT AND/OR ATTENUATE BRAIN DAMAGE IN PREMATURE INFANTS OTHER THAN SUPPORTIVE CARE AND THE ONLY AVAILABLE THERAPEUTIC INTERVENTION FOR FULL TERM INFANTS IS HYPOTHERMIA, WHICH IS ONLY PARTIALLY PROTECTIVE. INTER- ALPHA INHIBITOR PROTEINS (IAIP) ARE NATURALLY DERIVED GLYCOPROTEINS THAT HAVE BEEN SHOWN TO PLAY AN IMPORTANT ROLE IN MODULATING INFLAMMATORY RESPONSES BY DOWN-REGULATING PRO-INFLAMMATORY CYTOKINES IN SEVERAL EXPERIMENTAL MODELS OF NEWBORN AND ADULT SYSTEMIC INFLAMMATION AND IN MODELS OF INFLAMMATION-INDUCED PREMATURE LABOR. OUR RECENT INVESTIGATIONS STRONGLY DEMONSTRATE THAT IAIP REDUCED NEUROANATOMICAL INJURY IN THE BRAIN OF NEONATAL RATS AND IMPROVES LONG-TERM BEHAVIORAL INDICES OF LEARNING AND MEMORY TASKS. IN THE PHASE I SBIR STUDY, WE CONFIRMED THE BENEFICIAL EFFECTS OF IAIP IN NEONATAL RATS AFTER HI, PARTICULARLY IN MALE SUBJECTS. MORE RECENTLY, WE OBTAINED SUPPORTING EVIDENCE THAT IAIP ALSO HAS LONG-TERM BENEFICIAL EFFECTS ON BEHAVIORAL FUNCTION IN FEMALE RATS, SUGGESTING THAT IAIP HAS DURABLE NEUROPROTECTIVE EFFECTS IN BOTH MALES AND FEMALES DEPENDING UPON TEST AND THE DURATION AFTER THE HI INSULT. THESE FINDINGS SUGGEST UNIQUE BENEFICIAL EFFECTS OF IAIP ON LONG-TERM OUTCOMES IN MALES AND FEMALES, IN SPITE OUR HISTOPATHOLOGICAL BENEFICIAL FINDINGS MAINLY IN MALE NEONATAL RATS. THE GOAL OF THIS PHASE II SBIR PROJECT IS TO OBTAIN ROBUST PRECLINICAL AND MANUFACTURING PROCESS DATA OF HUMAN PLASMA-DERIVED IAIP TO SUPPORT THE DEVELOPMENT AS A NOVEL ADJUNCTIVE NEUROPROTECTIVE STRATEGY TO THE CURRENT STANDARD OF CARE OF HYPOTHERMIA FOR THE TREATMENT OF HYPOXIC-ISCHEMIC ENCEPHALOPATHY IN NEWBORNS. WE HYPOTHESIZE THAT TREATMENT WITH IAIP AS AN ADJUNCTIVE THERAPY TO HYPOTHERMIA FURTHER ENHANCES THE EFFECTIVENESS OF HYPOTHERMIA AS A NEUROPROTECTIVE STRATEGY AND IMPROVES LONG-TERM OUTCOMES AFTER HI BRAIN INJURY IN NEONATES. THE SPECIFIC AIMS OF THE STUDIES ARE: 1) TO DEVELOP AN EFFICIENT SCALABLE BIOPROCESS OF PLASMA-DERIVED IAIP AND CARRY OUT FORMULATION, VIRAL SAFETY AND LONG-TERM STABILITY STUDIES OF PURIFIED IAIP; 2A) TO DETERMINE THE PHARMACOKINETICS (PK) OF IAIP IN MALE AND FEMALE RATS UNDER CONDITIONS OF HYPOXIC-ISCHEMIC (HI) AND HYPOTHERMIA (HT) AND TO PERFORM DOSE-RESPONSE STUDIES; 2B) TO ASSESS THE NEUROPROTECTIVE EFFECTS OF IAIP AS AN ADJUNCTIVE TREATMENT STRATEGY TO HT IN MODERATE OR SEVERE HI BRAIN INJURY IN NEWBORN RATS AND 3) TO DETERMINE THE LONG-TERM NEUROPROTECTIVE EFFICACY OF IAIP TREATMENT WITH COMBINED HT AFTER HI IN THE NEWBORN RATS. THE PROPOSED STUDIES HAVE SIGNIFICANT TRANSLATIONAL POTENTIAL TO DEVELOP IAIP AS A NOVEL AGENT TO PREVENT/ATTENUATE BRAIN DAMAGE IN FULL TERM AS WELL AS IN PRETERM INFANTS AT RISK FOR MENTAL RETARDATION.
$0
6/16/21